Evidence map›Paper›PMID 37653116›Full record

ArticleOncogene2023

Retraction Note: Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress.

Y Shi, Y Yang, B Hoang, C Bardeleben, B Holmes, J Gera, A Lichtenstein

RetractedOpen access · bronzeAbstract readRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 72% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Y ShiDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
Y YangDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
B HoangDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
C BardelebenDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
B HolmesDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
J GeraDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA.
A LichtensteinDivision of Hematology-Oncology, UCLA-Greater Los Angeles VA Healthcare Center and Jonsson Comprehensive Cancer Center, VA West LA Hospital/Hematology-Oncology, W111H, West LA VA Hospital, Los Angeles, CA, USA. Alan.lichtenstein@med.va.gov.
UCLA Jonsson Comprehensive Cancer CenterVA West Los Angeles Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37653116
PMCPMC10562938
OpenAlexW4386329078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.